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Abstract
Background: Multiple sclerosis (MS) appears to develop in genetically susceptible individuals as a result of environmental
exposures. Epstein-Barr virus (EBV) infection is an almost universal finding among individuals with MS. Symptomatic EBV
infection as manifested by infectious mononucleosis (IM) has been shown in a previous meta-analysis to be associated with
the risk of MS, however a number of much larger studies have since been published.
Methods/Principal Findings: We performed a Medline search to identify articles published since the original meta-analysis
investigating MS risk following IM. A total of 18 articles were included in this study, including 19390 MS patients and 16007
controls. We calculated the relative risk of MS following IM using a generic inverse variance with random effects model. This
showed that the risk of MS was strongly associated with IM (relative risk (RR) 2.17; 95% confidence interval 1.97–2.39;
p,10254).
Discussion: Our results establish firmly that a history of infectious mononucleosis significantly increases the risk of multiple
sclerosis. Future work should focus on the mechanism of this association and interaction with other risk factors.
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Introduction
Multiple sclerosis (MS) is a complex neurological disorder
characterised by demyelination and axonal loss[1]. The relative
contribution of genetic and environmental factors to MS aetiology
is an area of fertile debate. It is becoming increasingly clear that a
multitude of genetic and environmental factors interact at different
points during the course of an individual’s life to determine disease
susceptibility[2]. These factors include the Human Leukocyte
Antigen (HLA) region, Epstein-Barr virus (EBV), vitamin D and
smoking[3,4,5].
The evidence implicating EBV in MS aetiology is growing[6].
MS patients are almost universally seropositive for EBV infection
(99.5%) although there is a very high rate of asymptomatic EBV
infection amongst control populations too (94.2%)[7,8]. Further-
more, high titres of antibodies against EBV have been shown to
predict conversion from the initial demyelination seen in a
clinically isolated syndrome (CIS) to definite MS[9]. Elevated
titres of antibodies directed against the latent phase antigen of
EBV infection are also correlated with disease activity on
MRI[10]. Finally, studies have suggested that a latitude gradient
exists for the incidence of IM, resembling that of MS[11,12].
EBV infection can occur either asymptomatically or present as
infectious mononucleosis (IM). A previous meta-analysis of cohort
and case-control studies have suggested that IM more than
doubles the risk of MS (relative risk (RR) 2.3; 95% confidence
interval (95% CI) 1.7–3.0; p,1028) [13]. Given the high rates of
asymptomatic EBV infection present both in patient and control
populations, this implicates IM as the manifestation of EBV
infection most associated with the development of MS. Since the
original meta-analysis of IM and MS was published several other
much larger studies have been directed towards understanding the
association between IM and MS. Establishing the precise
magnitude of the relationship between IM and MS is important
in understanding the role of EBV in MS and also for attempts at
risk prediction[14]. Therefore in the present study we aimed to
broaden the previous meta-analysis to include studies published
since 2006 to confirm the association of IM and MS and to see if
the relationship between IM and MS is latitude dependent.
Methods
Search Strategy
We searched Medline from January 2006 until April 2010 for
articles with the phrase: ‘‘(Epstein-Barr virus OR EBV OR human
herpesvirus 4 OR HHV-4 OR infectious mononucleosis OR
glandular fever) AND (multiple sclerosis OR MS OR disseminated
sclerosis)’’. This was the same strategy used by Thacker and
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colleagues in 2006[13]. We hand-searched abstracts generated
from this search term for cohort or case-control studies and
examined references of these articles for potential additional
studies. Experts in the field were unaware of any ongoing
unpublished studies for inclusion.
Statistical analysis
We used the generic inverse variance with random effects model
in Reference Manager 5.0 to calculate the overall RR, 95% CI
and test statistic for the interaction and heterogeneity of studies.
RRs were subsequently calculated for subgroups of studies and
compared between case-control and cohort studies, and studies
using definite MS diagnostic criteria and those using definite/
probable MS. We extracted latitude from papers based on either
the latitude of the study centre if performed in a distinct region or
the geographical midpoint of the country if a national study. We
tested for an interaction between latitude and sex-ratio by both a
comparison of RRs based on the median value for each factor and
also performed linear weighted fit on the natural log of RRs in
Mathematica 7.0.1.0.
Results
Included studies
Our search criteria produced 150 studies. We identified four
studies (one population cohort study and three case-control studies)
not included in the original meta-analysis, making a total of
18 studies[15,16,17,18,19,20,21,22,23,24,25,26,27,28,29,30,31,32].
The details of the studies included are shown in table S1. In terms
of case-control studies, the new studies increased the number of MS
cases included in the meta-analysis from 1642 to 19390 and controls
from 3596 to 16007. The RR in all studies had a range of 0.8–17 and
a median RR of 2.21.
Risk of MS following IM
Including all of the 18 identified studies in our meta-analysis, we
calculated a RR of 2.17 (95% CI 1.97–2.39; p,10254; figure 1).
There was no significant heterogeneity between studies (p = 0.47).
There were no significant differences detected when comparing
subgroups of studies based on design or diagnostic criteria, or
when dichotomised based on median latitude or sex-ratio
(table 1).
Interaction with latitude and sex-ratio
We tested both latitude and sex-ratio for correlation with the
RR for each study using linear weighted fit (figure 2). No
significant correlation was found for either (latitude: r2,0.01,
p = 0.91; sex-ratio: r2,0.01, p = 0.79).
Discussion
With an MS patient sample size an order of magnitude larger
than the previous meta-analysis, our study has established
unequivocally that IM is a significant risk factor for the development
of MS. The robust nature of this relationship is unsurprising given
the wealth of serological research implicating EBV in MS aetiology.
Meta-analysis has some limitations: notably publication bias of
included studies and heterogeneity of study designs[33]. We have
attempted to avoid these pitfalls in this study.
There was no strong evidence to suggest that the degree to
which IM influences MS susceptibility varies by latitude, however
the range of latitudes at which studies have been conducted is
Figure 1. Forest plot of multiple sclerosis risk after infectious mononucleosis.
doi:10.1371/journal.pone.0012496.g001
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relatively small. This study cannot exclude an effect of EBV
infection on MS latitudinal risk, as studies conducted so far include
predominantly Caucasian cases and controls or are studies of IM
and MS in predominantly Caucasian populations. Studies on
other populations also afflicted by MS would be valuable in
examining whether IM is a risk factor of equal magnitude in all
populations, especially since EBV is known to interact with certain
HLA alleles that vary in frequency between different popula-
tions[4]. MS susceptibility is defined by an interplay of many
different genetic and environment risk factors and so it is likely that
these all act in concert at different points in the disease process to
establish the well-described latitudinal gradient[34]. Thus it is
Table 1. Relative risk and 95% confidence intervals for different subgroups of studies.
Subgroup of studies Relative risk Lower 95% CI Upper 95% CI number of studies p-value for comparison
Case-control 2.11 1.82 2.43 14 0.39
Cohort 2.33 1.96 2.78 4
Definite MS 2.12 1.69 2.64 5 0.74
Definite/probable MS 2.21 1.97 2.47 10
Latitude ,54 2.01 1.51 2.67 9 0.56
Latitude $54 2.2 1.96 2.47 9
Sex-ratio ,2.12 2.03 1.54 2.67 7 0.61
Sex-ratio $2.12 2.21 1.85 2.63 8
P-values for comparison between subgroups are also shown.
doi:10.1371/journal.pone.0012496.t001
Figure 2. Plots of relative risk against latitude and sex-ratio. Error bars show 95% confidence intervals of relative risk estimates.
doi:10.1371/journal.pone.0012496.g002
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unsurprising that, even if IM has an important role in establishing
MS prevalence patterns, examining this risk factor alone did not
reveal any strong effects of IM in the latitudinal distribution of MS.
It is unsurprising that we detected no interaction between IM and
the sex-ratio of MS cases since there were no significant difference
between the rates of IM in males and females in a recent cohort
study[35].
The mechanism by which EBV infection is associated with MS
is currently poorly understood. One hypothesis is that infection of
any sort is an epiphenomenon in the development of MS,
reflecting a generally increased propensity to infection or generally
altered immune responses directed against infectious anti-
gens[36,37,38]. Certainly some studies have cast doubt upon the
specific role of current EBV infection in MS[39], although there is
little doubt that past EBV infection is an important risk factor[8].
An alternative is that a lack of exposure to infectious agents early
in life results in a failure of tolerance in the immune system: the
‘‘hygiene hypothesis’’[12]. This certainly fits with an increased rate
of IM in MS patients, since EBV infection later in life is more
likely to result in IM. However, it is difficult to reconcile this with
elevated MS risk in migrants moving from regions of low MS
prevalence to high prevalence[40]. Also, whereas one would
expect this to predict a difference in MS risk with birth order of
siblings (due to differing exposure to infectious antigens), this was
not observed in a large Canadian study[41].
IM has an important role in MS susceptibility but future work
needs to examine how IM rather than asymptomatic EBV
infection appears to be the main association with MS. The role
of EBV in MS remains to be elucidated and furthermore, of
increasing interest is attempts to understand how MS risk factors
interact that lead to the development of MS[2,8]. For this reason,
prospective studies should try to investigate the reasons why some
individuals present with IM after infection and why some of these
individuals then develop MS.
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